Assessing Efficacy and the Speed of Response in Psoriasis Treatment

Figures & data

Figure 1. Dose-response curves for drugs A-D. Increasing drug potency decreases half maximal effective concentration (EC₅₀).

Figure 2. PASI 90 response over time in ECLIPSE study (2). The efficacy of both drugs is similar at weeks 16 through 20, and then favors guselkumab to week 48. Speed of response illustrated using PASI90₅₀, favors secukinumab by more than one week.

Figure 3. Concentration-response curves illustrating the concept of potency. For a response of 25%, Drug B is more potent. For a response of 75%, Drug A is more potent.

Figure 4. PASI 75 response over time in FIXTURE study.³ Green and orange arrows indicate weeks to PASI75₅₀ for secukinumab 300 mg and etanercept respectively. Secukinumab 300 mg achieved PASI75₅₀ in less than 6 weeks compared to more than 13 weeks for etanercept.

Langley R, Blauvelt A, Armstrong A, et al. Proportion of patients achieving a PASI 90 response (with 95% confidence interval) through week 48 by visit. Guselkumab comparison to secukinumab in the treatment of adults with moderate to severe plaque psoriasis. Janssen Biotech, Inc. [cited 2019 Jun 27].

 Google Scholar